Additionally, the use of PARP inhibitors with bevacizumab in clinical trials (NCT02354131) have shown an impressive preliminary disease control rate of 92% in 12 patients with BRCA2-mutated ovarian cancers (33). Here, PARP1 is linked to ovarian cancer.